Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

281
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
281
Neural Regulation01:37

Neural Regulation

39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

567
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
567
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
Cholinergic Neurons: Neurotransmission01:23

Cholinergic Neurons: Neurotransmission

3.0K
Cholinergic neurotransmission involves the synthesis and the release of acetylcholine (ACh) in order to transmit nerve impulses across the synapse. The process begins with the synthesis of acetyl CoA, a precursor for ACh, from ATP, acetate, and coenzyme A in the mitochondria. Choline, another vital precursor, is transported inside the neuron through choline transporters, including high-affinity choline transporter CHT1, low-affinity choline transporter CTL1, and lower-affinity choline...
3.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Topography of Regional Cerebral GABA<sub>A</sub> Receptor Availability in Parkinson's Disease Patients With Freezing of Gait.

The European journal of neuroscience·2026
Same author

Neuropsychological impairments in emotion recognition compared to general cognition: profiles across six different neurological disorders.

Journal of neurology·2026
Same author

Excessive GABAergic activity in striatal and frontal cortical regions more than dopaminergic functions are related to daytime sleepiness in Parkinson's disease: An exploratory 11C-flumazenil PET study.

Geromedicine·2026
Same author

Cholinergic system changes in levodopa-unresponsive freezing of gait and failure of goal-directed motor behavior in Parkinson's disease.

Neural regeneration research·2026
Same author

White matter lesions disrupt cholinergic pathways important for cognition in Parkinson's disease.

Brain : a journal of neurology·2026
Same author

Associations of Monocyte Glucocerebrosidase with Cognition and Cholinergic Innervation in GBA1 Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026

Related Experiment Video

Updated: Jul 12, 2025

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

7.9K

Cholinergic centro-cingulate network in Parkinson disease and normal aging.

Nicolaas I Bohnen1,2,3,4, Sygrid van der Zee5,6, Roger Albin2,3,4,7

  • 1Department of Radiology, University of Michigan, Ann Arbor, MI 48105, USA.

Aging
|October 29, 2023
PubMed
Summary

Cholinergic deficits in the centro-cingulate network are linked to cognitive and motor issues in Parkinson disease (PD). These changes, also seen in normal aging, suggest combined therapeutic strategies may benefit neurodegenerative disorders.

Keywords:
Parkinson diseasecentro-cingulate networkcholinergiccognitionmotor

More Related Videos

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

15.7K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.2K

Related Experiment Videos

Last Updated: Jul 12, 2025

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

7.9K
Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

15.7K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.2K

Area of Science:

  • Neuroscience
  • Neurodegenerative Diseases
  • Cognitive Neurology

Background:

  • Cholinergic system dysfunction is implicated in Parkinson disease (PD) cognitive and motor impairments.
  • The centro-cingulate brain network, crucial for cognitive and motor control, shows reduced cholinergic binding in PD.
  • Normal aging also involves cholinergic nerve terminal vulnerabilities, particularly in the centro-cingulate network.

Purpose of the Study:

  • To explore the correlation between cholinergic binding in the centro-cingulate network and cognitive/motor deficits in PD.
  • To investigate the role of the anterior midcingulate cortex in motor control and somato-cognitive integration.
  • To understand the overlap between PD-related and age-related cholinergic system changes.

Main Methods:

  • Review of MRI neuroimaging studies on brain networks and cholinergic function.
  • Analysis of the relationship between centro-cingulate network integrity and PD symptom severity.
  • Examination of novel primary motor cortex organization related to effector and inter-effector control.

Main Results:

  • Decreased cholinergic binding in the centro-cingulate network strongly correlates with PD cognitive impairment severity.
  • This network also correlates with parkinsonian motor impairments like postural instability and gait difficulties.
  • Evidence suggests inter-effector regions in the motor cortex are linked to cingular and opercular regions, forming a somato-cognitive action network.

Conclusions:

  • Cholinergic deficits in the centro-cingulate network are central to PD pathophysiology.
  • Age-related cholinergic vulnerabilities contribute to neurodegeneration, suggesting shared etiological factors.
  • Therapeutic strategies targeting both disease-specific and aging-related mechanisms may be beneficial for neurodegenerative disorders with cholinergic system degeneration.